OBJECTIVES: Clinicians prescribe antihypertensive medication to children with primary hypertension, but without data to define a particular choice as first-line therapy. A one-size-fits-all approach may not be appropriate for these patients. Our aim was to develop a personalized approach to hypertension treatment, using repeated ambulatory blood pressure monitoring (ABPM) in n-of-1 trials (single-patient randomized crossover trials). METHODS:Children undergoing hypertension management at a single pediatric referral center were offered participation in an n-of-1 trial with repeated ABPM to compare 3 commonly used medications. The medication producing the greatest blood pressure reduction, and without unacceptable side effects, was selected as the preferred therapy for the individual. RESULTS:Forty-two children agreed to participate; 7 were normotensive without medication; and 3 failed to complete one treatment cycle. Of the remaining 32 patients, lisinopril was preferred for 16, amlodipine for 8, hydrochlorothiazide for 4, and 4 had uncontrolled blood pressure on maximum doses of monotherapy. In conservative Bayesian analyses, the proportion of patients who preferred lisinopril was 49% (95% credible interval [CrI]: 32% to 69%), 24% (95% CrI: 12% to 41%) preferred amlodipine, and 12% (95% CrI: 4% to 26%) preferred hydrochlorothiazide. The preferred therapy for the majority (67%) of African American participants was lisinopril. Unacceptable side effects were reported in 24% of assessments for hydrochlorothiazide, 16% for lisinopril, and 13% for amlodipine. CONCLUSIONS: No single medication was preferred for more than half of hypertensive children. n of-1 trials with repeated ABPM may promote better informed and individualized decisions in pediatric hypertension management.
RCT Entities:
OBJECTIVES: Clinicians prescribe antihypertensive medication to children with primary hypertension, but without data to define a particular choice as first-line therapy. A one-size-fits-all approach may not be appropriate for these patients. Our aim was to develop a personalized approach to hypertension treatment, using repeated ambulatory blood pressure monitoring (ABPM) in n-of-1 trials (single-patient randomized crossover trials). METHODS:Children undergoing hypertension management at a single pediatric referral center were offered participation in an n-of-1 trial with repeated ABPM to compare 3 commonly used medications. The medication producing the greatest blood pressure reduction, and without unacceptable side effects, was selected as the preferred therapy for the individual. RESULTS: Forty-two children agreed to participate; 7 were normotensive without medication; and 3 failed to complete one treatment cycle. Of the remaining 32 patients, lisinopril was preferred for 16, amlodipine for 8, hydrochlorothiazide for 4, and 4 had uncontrolled blood pressure on maximum doses of monotherapy. In conservative Bayesian analyses, the proportion of patients who preferred lisinopril was 49% (95% credible interval [CrI]: 32% to 69%), 24% (95% CrI: 12% to 41%) preferred amlodipine, and 12% (95% CrI: 4% to 26%) preferred hydrochlorothiazide. The preferred therapy for the majority (67%) of African American participants was lisinopril. Unacceptable side effects were reported in 24% of assessments for hydrochlorothiazide, 16% for lisinopril, and 13% for amlodipine. CONCLUSIONS: No single medication was preferred for more than half of hypertensivechildren. n of-1 trials with repeated ABPM may promote better informed and individualized decisions in pediatric hypertension management.
Authors: Joy M Schmitz; Charles E Green; Khader M Hasan; Jessica Vincent; Robert Suchting; Michael F Weaver; F Gerard Moeller; Ponnada A Narayana; Kathryn A Cunningham; Kelly T Dineley; Scott D Lane Journal: Addiction Date: 2017-07-03 Impact factor: 6.526
Authors: Ronald J Hogg; Angela Delucchi; Graciela Sakihara; Thomas G Wells; Frank Tenney; Donald L Batisky; Jeffrey L Blumer; Beth A Vogt; Man-Wai Lo; Elizabeth Hand; Deborah Panebianco; Ronda Rippley; Wayne Shaw; Shahnaz Shahinfar Journal: Pediatr Nephrol Date: 2007-01-10 Impact factor: 3.714
Authors: Elizabeth O Lillie; Bradley Patay; Joel Diamant; Brian Issell; Eric J Topol; Nicholas J Schork Journal: Per Med Date: 2011-03 Impact factor: 2.512
Authors: Robert J Kuczmarski; Cynthia L Ogden; Shumei S Guo; Laurence M Grummer-Strawn; Katherine M Flegal; Zuguo Mei; Rong Wei; Lester R Curtin; Alex F Roche; Clifford L Johnson Journal: Vital Health Stat 11 Date: 2002-05
Authors: C Jane Nikles; Geoffrey K Mitchell; Chris B Del Mar; Alexandra Clavarino; Norma McNairn Journal: Pediatrics Date: 2006-06 Impact factor: 7.124
Authors: Joseph T Flynn; Stephen R Daniels; Laura L Hayman; David M Maahs; Brian W McCrindle; Mark Mitsnefes; Justin P Zachariah; Elaine M Urbina Journal: Hypertension Date: 2014-03-03 Impact factor: 10.190
Authors: R A Preston; B J Materson; D J Reda; D W Williams; R J Hamburger; W C Cushman; R J Anderson Journal: JAMA Date: 1998-10-07 Impact factor: 56.272
Authors: Joyce P Samuel; Alyssa Burgart; Susan H Wootton; David Magnus; John D Lantos; Jon E Tyson Journal: Pediatrics Date: 2016-07-06 Impact factor: 7.124
Authors: Sunita Vohra; Larissa Shamseer; Margaret Sampson; Cecilia Bukutu; Christopher H Schmid; Robyn Tate; Jane Nikles; Deborah R Zucker; Richard Kravitz; Gordon Guyatt; Douglas G Altman; David Moher Journal: BMJ Date: 2015-05-14
Authors: Heather C Kaplan; Lisa Opipari-Arrigan; Christopher H Schmid; Christine L Schuler; Shehzad Saeed; Kimberly L Braly; Jennifer C Burgis; Kaylie Nguyen; Sheri Pilley; Julie Stone; Gisele Woodward; David L Suskind Journal: Healthcare (Basel) Date: 2019-11-01
Authors: Catherine G Derington; Jordan B King; Thomas Delate; Sheila R Botts; Miranda Kroehl; David P Kao; Katy E Trinkley Journal: PLoS One Date: 2020-12-03 Impact factor: 3.240
Authors: Ying Kuen Cheung; Dallas Wood; Kangkang Zhang; Ty A Ridenour; Lilly Derby; Tara St Onge; Naihua Duan; Joan Duer-Hefele; Karina W Davidson; Ian Kronish; Nathalie Moise Journal: BMJ Open Date: 2020-06-07 Impact factor: 2.692